HUGE NEWS: CEO Presentation Today
StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the 2014 BIO International
2014-06-23 12:00:27.771 GMT
StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative
Medicine Panel at the 2014 BIO International Convention
NEWARK, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that President and CEO Martin McGlynn will be a
panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm
PDT. Mr. McGlynn will participate in the panel discussion, "How International
Collaboration is Accelerating the Field." This panel will showcase examples of
international collaboration that are producing results or initiating new
approaches to cross-border research. Under Mr. McGlynn's leadership,
StemCells, Inc. launched a multi-national Phase I/II trial in spinal cord
injury. The pre-clinical activities were performed in the United States and
followed by the initiation of the clinical trial in Switzerland, which was
subsequently expanded to both Canada and the United States. The success of
these programs is a great example of how international collaboration can
produce results that positively impact the lives of patients across the globe.
The 2014 BIO International Convention will take place June 23-26 at the San
Diego Convention Center in San Diego, CA.
Additional information on the conference and the panel presentation can be
found on the conference website at:
http://convention.bio.org/
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells. The Company conducted a Phase I/II clinical
trial in chronic spinal cord injury in Switzerland, Canada and the United
States, and has reported positive interim data for the first eight
patients. The Company is also conducting a Phase I/II clinical trial in dry
age-related macular degeneration (AMD) in the United States. In addition, the
Company is pursuing preclinical studies in Alzheimer's disease, with support
from the California Institute for Regenerative Medicine (CIRM). StemCells
also markets stem cell research products, including media and reagents, under
the SC Proven® brand. Further information about StemCells is available at
http://www.stemcellsinc.com.
CONTACT: Greg Schiffman
StemCells, Inc.
Chief Financial Officer
(510) 456-4128
Andrea Flynn
Russo Partners
(646) 942-5631
News 
Market Data 
Discover 
AI
